Goldman Sachs analyst Amit Hazan upgraded Inspire Medical to Buy from Neutral with a price target of $308, up from $245. Given "strong visibility" and the company’s "track record of execution," Hazan sees upside to current consensus and expects "strong" upcoming 2023 guidance, the analyst tells investors. Given multiple compression over the last six months relative to the group, the shares now offer a much better risk/reward, added the analyst, who names Inspire as his top Medtech midcap for 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical initiated with an Overweight at KeyBanc
- Inspire Medical Systems, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
- Inspire Medical Systems, Inc. Announces Third Quarter 2022 Financial Results and Updates 2022 Outlook
- TipRanks ‘Perfect 10’ List: These 2 Stocks Tick All the Boxes
